Daraxonrasib for KRAS-mutant biliary tract cancer after prior therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called daraxonrasib for people with a type of bile duct or gallbladder cancer that has a specific genetic change (KRAS mutation) and has progressed after one prior treatment. The drug targets the mutated KRAS protein to potentially slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bile duct or gallbladder cancer that cannot be removed by surgery or has spread.
- Your cancer must have a specific genetic change called a KRAS mutation.
- You must have received at least one prior chemotherapy (with or without immunotherapy) and your cancer got worse or you couldn't tolerate the treatment.
- You must be at least 18 years old.
- You need to be in generally good health (able to do light activity) and have adequate organ function.
- You must agree to provide tumor tissue and blood samples for research and to use birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program gives early access to an experimental pill called daraxonrasib for people whose pancreatic cancer has spread and has not responded to previous chemotherapy. It is not a regular clinical trial but a way to try the drug if no other options are available.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.